Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

Table 3

QoL based on the EQ-5D.

	Statistic	All (𝑁=116)	mSTS (𝑁=96)	mBS (𝑁=20)
Mobility	N (%)
No problems		64 (55.2%)	52 (54.2%)	12 (60%)
Some problems		48 (41.4%)	40 (41.7%)	8 (40%)
Confined to bed		4 (3.5%)	4 (4.2%)	0
Missing		0	0	0
Self-care	N (%)
No problems		95 (81.9%)	75 (78.1%)	20 (100%)
Some problems		20 (17.2%)	20 (20.8%)	0
Unable to wash or dress myself		0	0	0
Missing		1 (0.9%)	1 (1%)	0
Usual activities	N (%)
No problems		48 (41.4%)	43 (44.8%)	5 (25%)
Some problems		60 (51.7%)	46 (47.9%)	14 (70%)
Unable to perform usual activities		7 (6%)	6 (6.3%)	1 (5%)
Missing		1 (0.9%)	1 (1%)	0
Pain/discomfort	N (%)
No pain/discomfort		44 (37.9%)	38 (39.6%)	6 (30%)
Moderate pain/discomfort		66 (56.9%)	54 (56.3%)	12 (60%)
Extreme pain/discomfort		6 (5.2%)	4 (4.2%)	2 (10%)
Missing		0	0	0
Anxiety/depression	N (%)
Not anxious/depressed		64 (55.2%)	53 (55.2%)	11 (55%)
Moderately anxious/depressed		49 (42.2%)	41 (42.7%)	8 (40%)
Extremely anxious/depressed		3 (2.6%)	2 (2.1%)	1 (5%)
Missing		0	0	0
Utility score^1	N	114	94	20
	Mean (SD)	0.69 (0.26)	0.69 (0.26)	0.68 (0.27)
	Median	0.73	0.73	0.74
	Min, max	−0.08, 1	−0.08, 1	−0.08, 1
	95% CI	0.64, 0.73	0.64, 0.74	0.55, 0.8
VAS score ^2	N	116	96	20
	Mean (SD)	64.97 (20.14)	65.75 (19.63)	61.25 (22.63)
	Median	70	70	65
	Min, max	0, 100	0, 100	15, 90
	95% CI	61.27, 68.68	61.77, 69.73	50.66, 71.84

Note: mSTS: metastatic soft tissue sarcoma, mBS: metastatic bone sarcoma; ¹range −0.59 (worse than death)—1 (full health); ²range 0 (worst imaginable health)—100 (best imaginable health).